Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Startup from George Church’s lab raises $75M to develop …
WEB2 days ago · A new company born out of research done by top Harvard genetic scientist George Church is promising to “revolutionize cell therapy.”. The company, GC Therapeutics, announced its launch Thursday with $75 million in financing from investors including Cormorant Asset Management and Mubadala Capital. Its board and list of advisers includes John ...
Novo sinks on obesity drug results; Sanofi reveals anticipated MS …
WEB1 day ago · Sanofi on Friday presented study results the company has claimed could support approval of its experimental drug tolebrutinib in a form of multiple sclerosis. The data showed tolebrutinib helped delay the time to onset of confirmed disability progression by 31% compared to a placebo in people with non …
Biotech News - BioPharma Dive
WEBSep 13, 2024 · ArsenalBio raises $325M in one of the year’s largest biotech funding rounds. The financing comes amid a slowdown in venture investment for gene and cell therapy startups, and will support multiple solid tumor programs. By Gwendolyn Wu • Sept. 4, 2024. News roundup.
Pharma News | BioPharma Dive
WEBSep 13, 2024 · Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise. OrsoBio is advancing several weight loss medicines. Elsewhere, Boehringer Ingelheim pushed forward with a geographic atrophy drug and Vaxcyte raised $1.3 billion. By BioPharma Dive staff • Sept. 6, 2024. Access now .
GSK antibody drug reduces COPD attacks in trial | BioPharma Dive
WEBSep 6, 2024 · Dive Brief: GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive pulmonary disease, offering the British drugmaker another shot at an expanded approval for the drug; The trial, known as MATINEE, included COPD patients suffering from chronic bronchitis and/or emphysema who were already taking inhaled therapies and showed evidence of a certain ...
10 clinical trials to watch in the first half of 2024
WEBJan 2, 2024 · Moderna and Pfizer both reported promising results in early testing last fall and have moved on to late-stage studies. Moderna appears positioned to get to the finish line first. Results from its Phase 3 trial could be coming in the first half of this year, according to a federal database. — Delilah Alvarado.
Clinical Trial News - BioPharma Dive
WEB4 days ago · Keytruda fails lung and skin cancer trials, limiting further expansion. The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion. By Jonathan Gardner • Aug. 29, 2024.
Deep Dive - BioPharma Dive
WEBJun 27, 2024 · A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology. Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. Jonathan Gardner • Sept. 4 ...
Iovance, with approval of ‘TIL’ cell therapy, readies for complex ...
WEBFeb 20, 2024 · Dive Insight: Amtagvi’s approval has been a long time coming for Iovance. TIL therapy originated from research at the National Institutes of Health in the 1980s.It took decades to fine-tune, and Iovance had to overcome multiple regulatory delays bringing the therapy, formerly known as lifileucel, to market.. Its clearance is the “culmination of scientific and clinical research efforts ...
Skip to content